sar425899 sanofi dual agonist glp-1 glucagon Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes - Cheang - 2018 - ChemMedChem The molecular pharmacology of glucagon

However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects

Are you a candidate?

Not for use during pregnancy or nursing without guidance from your provider

Glucagon-like-peptide-1 receptor agonists (GLP-1s) have transformed weight management and treatment of chronic disease

Premium Quality Supplements to Support Your Healthy Journey*

Recent phase 2 and phase 3 clinical trials have established the therapeutic value of various GLP-1 RAs in improving liver histology and metabolic parameters in patients with MASH